4.7 Article

Targeting the BMK1 MAP Kinase Pathway in Cancer Therapy

期刊

CLINICAL CANCER RESEARCH
卷 17, 期 11, 页码 3527-3532

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-2504

关键词

-

类别

资金

  1. NIH [CA079871, CA114059]
  2. University of California [19XT-0084]

向作者/读者索取更多资源

The big mitogen activated protein kinase 1 (BMK1) pathway is the most recently discovered and least-studied mammalian mitogen-activated protein (MAP) kinase cascade, ubiquitously expressed in all types of cancer cells tested so far. Mitogens and oncogenic signals strongly activate this cellular MAP kinase pathway, thereby passing down proliferative, survival, chemoresistance, invasive, and angiogenic signals in tumor cells. Recently, several pharmacologic small molecule inhibitors of this pathway have been developed. Among them, the BMK1 inhibitor XMD8-92 blocks cellular BMK1 activation and significantly suppresses tumor growth in lung and cervical tumor models and is well tolerated in animals. On the other hand, MEK5 inhibitors, BIX02188, BIX02189, and compound 6, suppress cellular MEK5 activity, but no data exist to date on their effectiveness in animals. Clin Cancer Res; 17(11); 3527-32. (C)2011 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据